Bioasis, which is developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier, has entered into a research collaboration and license agreement with Neuramedy Co Ltd of Seoul, Korea.
Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2. Tomaralimab is currently in development for the treatment of Parkinson’s disease and Multiple System Atrophy.